Advertisement

Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12

  • Satoshi IkedaEmail author
  • Eiichiro Nakamura
  • Kenichiro Narusawa
  • Fumio Fukuda
  • Hidehiro Matsumoto
  • Kenichiro Nakai
  • Takeshi Sakata
  • Toru Yoshioka
  • Yoshihisa Fujino
  • Akinori Sakai
  • KOTU T-WRAP Study Investigators
Original Article
  • 2 Downloads

Abstract

The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week after onset of the fracture. Patients were randomly allocated to the teriparatide and alendronate groups. Vertebral collapse, low back pain assessed by a visual analog scale, and QOL assessed by EuroQol 5 dimension at weeks 1, 2, 4, 8, and 12 after the start of the treatment were compared between the groups. Lumbar bone mineral density (BMD) at baseline and week 12 and the rate of delayed union at week 12 were also compared. Each group consisted of 48 subjects. Vertebral collapse progressed over time in both groups, with no significant difference between the groups. Pain on rising up from lying position, turning over in bed, and resting in the lying position improved over time in both groups, with no significant difference between the groups. There were no significant differences in increase in BMD and delayed union. QOL in the teriparatide group showed significant improvement in comparison with that in the alendronate group at week 12. The weekly formulation of teriparatide showed comparable inhibition of vertebral collapse, increase in BMD, promotion of bone union, and improvement of pain and significant improvement of QOL at week 12 in comparison with alendronate in patients with a new osteoporotic vertebral fracture within 1 week after onset of the fracture. The weekly formulation of teriparatide may have improved components of QOL other than pain at week 12.

Keywords

EuroQol 5 dimension Delayed union Kyphosis angle Visual analog scale Wedge angle 

Notes

Acknowledgements

The authors would like to express their gratitude to the study patients for their participation. The authors would also like to acknowledge the assistance of Kazumasa Tanzawa, EPS Corporation and KOTU T-WRAP study Investigators. The study was funded by the Asahi Kasei Pharma Corporation.

Author contributions

SI designed the study and wrote the initial draft of the manuscript. Other authors have contributed to data collection and interpretation, and critically reviewed the manuscript. All authors contributed to analysis and interpretation of data, approved the final version of the manuscript, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Compliance with ethical standards

Conflict of interest

S. Ikeda has received payments for lectures, including speakers’ bureau fees, from Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., and Teijin Pharma Ltd. A Sakai has received lecture fee from Asahi Kasei Pharma Corporation and Chugai Pharmaceutical Co., Ltd. E Nakamura, K Narusawa, F Fukuda, H Matsumoto, K Nakai, T Sakata, T Yoshioka, and Y Fujino declare that they have no conflict of interest.

Ethical approval

The study protocol and associated documents used in this study were reviewed and approved by the internal review board at each study site in accordance with the Declaration of Helsinki. All procedures in this study involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all individual participants included in this study before initiating any procedures.

References

  1. 1.
    United Nations, World Population Prospects: The 2015 Revision UN Department of Economic and Social Affairs GenevaGoogle Scholar
  2. 2.
    Kitazawa A, Kushida K, Yamazaki K, Inoue T (2001) Prevalence of vertebral fractures in a population-based sample in Japan. J Bone Miner Metab 19:115–118CrossRefGoogle Scholar
  3. 3.
    Yoshimura N, Kinoshita H, Danjoh S, Yamada H, Tamaki T, Morioka S, Kasamatsu T, Hashimoto T, Inoue T (1995) Prevalence of vertebral fractures in a rural Japanese population. J Epidemiol 5:171–175CrossRefGoogle Scholar
  4. 4.
    Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton Lj (1995) Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24:1171–1177CrossRefGoogle Scholar
  5. 5.
    Lindsay R, Silverman SL, Cooper C, hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2002) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323CrossRefGoogle Scholar
  6. 6.
    Yamaguchi T, Sugimoto T, Yamada H, Kanzawa M, Yano S, Yamauchi M, Chihara K (2002) The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporos Int 13:331–336CrossRefGoogle Scholar
  7. 7.
    Yamaguchi T, Sugimoto T, Yamauchi M, Matsumori Y, Tsutsumi M, Chihara K (2005) Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J Bone Miner Metab 23:36–40CrossRefGoogle Scholar
  8. 8.
    Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR (2007) Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 22:447–457CrossRefGoogle Scholar
  9. 9.
    Schlaich C, Minne HW, Bruckner T, Wagner G, Gebest HJ, Grunze M, Ziegler R, Leidig-Bruckner G (1998) Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 8:261–267CrossRefGoogle Scholar
  10. 10.
    Ataka H, Tanno T, Yamazaki M (2009) Posterior instrumented fusion without neural decompression for incomplete neurological deficits following vertebral collapse in the osteoporotic thoracolumbar spine. Eur Spine J 18:69–76CrossRefGoogle Scholar
  11. 11.
    Miyakoshi N, Kobayashi T, Suzuki T, Kikuchi K, Kasukawa Y, Shimada Y (2017) Perioperative medical complications after posterior approach spinal instrumentation surgery for osteoporotic vertebral collapse: a comparative study in patients with primary osteoporosis and those with secondary osteoporosis. Asian Spine J 11:756–762CrossRefGoogle Scholar
  12. 12.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106CrossRefGoogle Scholar
  13. 13.
    Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1–34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960–968CrossRefGoogle Scholar
  14. 14.
    Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42:90–97CrossRefGoogle Scholar
  15. 15.
    Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93:1583–1587CrossRefGoogle Scholar
  16. 16.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541Google Scholar
  17. 17.
    Hansson L, Hedner T, Dahlöf B (1992) Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1:113–119CrossRefGoogle Scholar
  18. 18.
    Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148CrossRefGoogle Scholar
  19. 19.
    Park JH, Kang KC, Shin DE, Koh YG, Son JS, Kim BH (2014) Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture. Osteoporos Int 25:613–618CrossRefGoogle Scholar
  20. 20.
    van der Poest Clement E, van Engeland M, Adèr H, Roos JC, Patka P, Lips P (2002) Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17:2247–2255CrossRefGoogle Scholar
  21. 21.
    Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M (2014) Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int 25:1173–1180CrossRefGoogle Scholar
  22. 22.
    Okimoto N, Uemura Y, Yoshioka T, Arita S, Tsurukami H, Otomo H, Nishida S, Ogawa T, Hirao k, Ikeda S, Matsumoto H, Toten Y, Katae Y, Okazaki Y, Nakagawa T, Sakai A (2018) Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: an open-label, prospective, observational study. Health Sci Rep 2:e107.  https://doi.org/10.1002/hsr2.107 CrossRefGoogle Scholar
  23. 23.
    Tsuchie H, Miyakoshi N, Kasukawa Y, Nishi T, Abe H, Segawa T, Shimada Y (2016) The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture. J Bone Miner Metab 34:86–91CrossRefGoogle Scholar
  24. 24.
    Kim DY, Lee SH, Jang JS, Chung SK, Lee HY (2004) Intravertebral vacuum phenomenon in osteoporotic compression fracture: report of 67 cases with quantitative evaluation of intravertebral instability. J Neurosurg 100:24–31CrossRefGoogle Scholar
  25. 25.
    Wu CT, Lee SC, Lee ST, Chen JF (2006) Classification of symptomatic osteoporotic compression fractures of the thoracic and lumbar spine. J Clin Neurosci 13:31–38CrossRefGoogle Scholar
  26. 26.
    Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C, Lems WF, Marin F (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 166:87–97CrossRefGoogle Scholar
  27. 27.
    Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F (2009) Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 85:484–493CrossRefGoogle Scholar
  28. 28.
    Soen S, Fujiwara S, Takayanagi R, kajimoto K, Tsujimoto M, Kimura S, Sato M, Krege JH, Enomoto H (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Curr Med Res Opin 33:2049–2056CrossRefGoogle Scholar
  29. 29.
    Hagino H, Soen S, Sugimoto T, Endo N, Okazaki R, Tanaka K, Nakamura T (2019) Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan. J Bone Miner Metab 37:273–281CrossRefGoogle Scholar

Copyright information

© The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Satoshi Ikeda
    • 1
    Email author
  • Eiichiro Nakamura
    • 2
  • Kenichiro Narusawa
    • 3
  • Fumio Fukuda
    • 4
  • Hidehiro Matsumoto
    • 5
  • Kenichiro Nakai
    • 6
  • Takeshi Sakata
    • 7
  • Toru Yoshioka
    • 8
  • Yoshihisa Fujino
    • 9
  • Akinori Sakai
    • 2
  • KOTU T-WRAP Study Investigators
  1. 1.Department of Orthopaedic SurgeryKen-Ai Memorial HospitalOngaJapan
  2. 2.Department of Orthopaedic SurgeryUniversity of Occupational and Environmental HealthKitakyushuJapan
  3. 3.Department of Orthopaedic SurgeryNakashibetsu Town HospitalNakashibetsuJapan
  4. 4.Department of Orthopaedic SurgeryKitakyushu General HospitalKitakyushuJapan
  5. 5.Department of Orthopaedic SurgerySanzai HospitalMiyazakiJapan
  6. 6.Department of Orthopaedic SurgeryMoriguchi Ikuno Memorial HospitalMoriguchiJapan
  7. 7.Department of Orthopaedic SurgeryKitade HospitalGoboJapan
  8. 8.Department of Orthopaedic SurgeryShimura HospitalHiroshimaJapan
  9. 9.Department of Environmental Epidemiology, Institute of Industrial Ecological SciencesUniversity of Occupational and Environmental HealthKitakyusyuJapan

Personalised recommendations